not used title
not used title
Today PhRMA released a new report that analyzes the share of new medicines that are available in over 70 countries and how long patients wait to receive them.
The Global Access to New Medicines Report includes comprehensive comparisons across countries in the G20, Organization for Economic Co-operation and Development (OECD) and several geographic regions.
A record number of new medicines are launching globally, but patients in most countries — including many developed countries — can access only a small share. On average, patients in OECD countries have access to only 29% of new medicines through a government health plan, while patients in the United States have access to 85%. In addition, patients in OECD countries wait an average of 41 months longer than patients in the United States for their government health plan to cover new medicines.
The report shines a light on the impact of policies that let governments act as gatekeepers between patients and new treatments. Most of the delay in patient access across OECD countries occurs after a new medicine has been approved as safe and effective by the local regulatory authority and often even after the product has been shipped by the manufacturer. For example, in Canada, 45% of new medicines were approved and launched by manufacturers 17 months after global first launch, but most patients in Canada wait nearly three more years for those medicines to be covered by their local government plan.
The report also shows that the United States is the world’s engine of biopharmaceutical innovation, with the most global first launches, the highest share of new medicines available and the fastest access for patients. However, provisions of the Inflation Reduction Act that impose government price setting threaten to reduce the number of new medicines being developed for patients around the world and could jeopardize access globally and in the United States.
Policymakers in all countries can enable timely patient access to new medicines by having strong intellectual property rights and enforcement, science-based and globally-harmonized regulatory review, and transparent pricing and reimbursement policies that value innovation. The perils of anti-innovation policies are catalogued in PhRMA’s recent submissions to the U.S. Trade Representative for the annual National Trade Estimate Report and Special 301 Report.
Please click here to download the full Global Access to New Medicines Report.
Richard Kane
Richard Kane is deputy vice president of international policy at the Pharmaceutical Research and Manufacturers of America (PhRMA). Richard leads PhRMA’s international market access and data analytics team. He previously worked in the U.S. government as a senior economist in the Office of Management and Budget, Executive Office of the President and as a senior economist in the Bureau of Economic Analysis at the U.S. Department of Commerce. Richard also previously worked at a private consulting firm, Avalere Health, where he helped lead their policy analytics team.
Richard Kane
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Setting the record straight: 3 facts about drug patents
July 13, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings
June 2, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
Argentina sets course to enable innovation by rejecting failed patent rules
March 26, 2026
16 years later: How BPCIA continues to expand competition and lower costs
March 23, 2026
Key context is often missing from the debate over the Patent Trial and Appeal Board
March 20, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
February 2, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
How post-approval innovation keeps delivering for patients
December 9, 2025
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
What seniors can expect this open enrollment
October 14, 2025
Three things to know about Bayh-Dole: Innovation that pays off for taxpayers
October 9, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
New report: How intellectual property drives U.S. innovation and biopharma's impact
June 30, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
April 30, 2025
USTR 2025 Special 301 Report corrects course
April 29, 2025
From sound to science: How IP powers innovation in music and hearing
April 25, 2025
How the IRA is impacting the generic drug market
April 8, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Reimagining patient access through meaningful policy reform
November 5, 2024
CMS needs to do better
November 4, 2024
PhRMA submission calls for USTR to correct course on trade policy, enforcement
October 18, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
September 24, 2024
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Biden Administration report debunks myths around patent “evergreening” and “thickets”
September 3, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
What to know about the latest effort to break patents using a legally dubious avenue
August 21, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
August 12, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
PhRMA launches education campaign on the benefits of America's IP system
June 26, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Experts discuss the value of IP at Senate Judiciary Committee hearing
May 28, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
May 23, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
World IP Day 2024: Supporting an innovative and sustainable future
April 26, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
ICYMI: Voter priorities this election season
April 18, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
International meetings hold big implications for Americans and our innovation ecosystem
February 26, 2024
The truth about Nebraska's price setting push
February 13, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
January 31, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
January 25, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
December 19, 2023
The White House continues to attack American innovation
December 15, 2023
Biosimilars drive savings, but the IRA undermines their development
December 14, 2023
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
November 29, 2023
Misuse of march-in could stifle innovation
November 27, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
Don't close the door on rare disease research
November 13, 2023
Word of the Month: The Bayh-Dole Act
November 8, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
October 24, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
4 truths about state government price setting
October 10, 2023
Word of the Month: AMR
September 27, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
It’s PBMs, not patents, blocking competition
September 14, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Three concerns about Colorado's approach to government price setting
August 23, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
Michigan proposal jeopardizes access to medicines
August 21, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
WTAS on reasonable pricing and public-private partnerships
August 8, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Reject efforts to undermine America’s R&D ecosystem
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
May 18, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
Setting the record straight on the Bayh-Dole Act and March-in
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
New resource underscores the importance of small molecule medicines
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
U.S. biopharmaceutical exports support jobs, innovation
March 20, 2023
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
March 13, 2023
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
February 28, 2023